Natera shares slide as investors weigh near-term sentiment headwinds ahead of upcoming earnings

Natera, Inc. (NTRA) is down 6.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The day’s drop does not appear tied to a single new company release, and instead looks driven by sentiment and positioning. This could be because investors are de-risking ahead of Natera’s next earnings report, with the stock also contending with recent analyst caution and recurring insider-sale headlines that can weigh on momentum names.

Details:

Natera’s next earnings report is scheduled for May 7, 2026, which can lead to short-term volatility as traders adjust exposure into the print.

The company guided to 2026 total revenue of $2.62 billion to $2.70 billion and gross margin of about 63% in its most recent full-year results update, which some investors may view as a tougher setup after a strong prior-year growth rate.

An April 2026 downgrade to a hold rating circulated in market summaries, alongside an insider sale disclosed around early April, both of which can pressure near-term sentiment even without a fundamental change.

Natera’s investor relations site also shows multiple Form 144 filings (proposed sales of securities) earlier in 2026, which can keep supply/overhang concerns in focus.

Sources:

Natera Investor Relations, MarketBeat, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NTRA Insider Trading Activity

$NTRA insiders have traded $NTRA stock on the open market 198 times in the past 6 months. Of those trades, 0 have been purchases and 198 have been sales.

Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:

STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 23 sales selling 348,040 shares for an estimated $75,455,675.
MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 26 sales selling 240,000 shares for an estimated $46,295,059.
MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 16 sales selling 75,778 shares for an estimated $17,927,148.
ROELOF BOTHA has made 0 purchases and 11 sales selling 75,000 shares for an estimated $17,708,935.
SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 28 sales selling 50,908 shares for an estimated $11,579,181.
HERM ROSENMAN has made 0 purchases and 4 sales selling 48,419 shares for an estimated $11,011,477.
JONATHAN SHEENA has made 0 purchases and 55 sales selling 44,968 shares for an estimated $9,781,469.
DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 16 sales selling 41,435 shares for an estimated $9,087,227.
JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 7 sales selling 24,158 shares for an estimated $5,643,144.
ROY D. BAYNES has made 0 purchases and 8 sales selling 12,780 shares for an estimated $2,809,688.
ROWAN E CHAPMAN has made 0 purchases and 3 sales selling 4,488 shares for an estimated $1,084,737.
GAIL BOXER MARCUS sold 122 shares for an estimated $24,242

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$NTRA Hedge Fund Activity

We have seen 406 institutional investors add shares of $NTRA stock to their portfolio, and 334 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

COATUE MANAGEMENT LLC added 2,463,008 shares (+1446.1%) to their portfolio in Q4 2025, for an estimated $564,250,502
WELLINGTON MANAGEMENT GROUP LLP added 2,420,263 shares (+94.7%) to their portfolio in Q4 2025, for an estimated $554,458,050
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,307,662 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $528,662,287
JPMORGAN CHASE & CO added 1,225,420 shares (+10.5%) to their portfolio in Q4 2025, for an estimated $280,731,467
RTW INVESTMENTS, LP removed 1,093,645 shares (-42.2%) from their portfolio in Q4 2025, for an estimated $250,543,133
PRICE T ROWE ASSOCIATES INC /MD/ removed 1,075,426 shares (-9.0%) from their portfolio in Q4 2025, for an estimated $246,369,342
CITADEL ADVISORS LLC removed 786,720 shares (-87.7%) from their portfolio in Q4 2025, for an estimated $180,229,684

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$NTRA Government Contracts

We have seen $463,800 of award payments to $NTRA over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $154,100
GENETIC TESTING: $79,200

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$NTRA Analyst Ratings

Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 04/14/2026
Canaccord Genuity issued a "Buy" rating on 12/22/2025
BTIG issued a "Buy" rating on 12/05/2025
JP Morgan issued a "Overweight" rating on 11/25/2025
UBS issued a "Buy" rating on 11/18/2025
Stephens & Co. issued a "Overweight" rating on 11/13/2025
Piper Sandler issued a "Overweight" rating on 11/11/2025

To track analyst ratings and price targets for $NTRA, check out Quiver Quantitative's $NTRA forecast page.

$NTRA Price Targets

Multiple analysts have issued price targets for $NTRA recently. We have seen 13 analysts offer price targets for $NTRA in the last 6 months, with a median target of $260.0.

Here are some recent targets:

Tejas Savant from Morgan Stanley set a target price of $250.0 on 03/03/2026
Catherine Ramsey from Baird set a target price of $257.0 on 02/27/2026
Daniel Markowitz from Evercore ISI Group set a target price of $260.0 on 02/27/2026
Brandon Couillard from Wells Fargo set a target price of $215.0 on 02/27/2026
Patrick Donnelly from Citigroup set a target price of $300.0 on 01/07/2026
Subbu Nambi from Guggenheim set a target price of $270.0 on 01/05/2026
Kyle Mikson from Canaccord Genuity set a target price of $285.0 on 12/22/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.